PBE - Invesco Dynamic Biotechnology & Genome ETF
|Ex-Dividend Date||Mar 23, 2020|
|Trading Day||April 16|
|Day's Range||74.24 - 76.67|
|52-Week Range||51.07 - 84.86|
The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
|Asset Class |
|Inception Date |
Jun 23, 2005
|Ticker Symbol |
|Index Tracked |
Dynamic Biotechnology & Genome Intellidex Index
Top 10 Holdings48.41% of assets
|Five Prime Therapeutics||FPRX||4.44%|
|Mar 23, 2020||$0.029||Mar 31, 2020|
|Sep 24, 2018||$0.002||Sep 28, 2018|
|Jun 16, 2017||$0.215||Jun 30, 2017|
|Mar 17, 2017||$0.056||Mar 31, 2017|
|Dec 16, 2016||$0.121||Dec 30, 2016|
|Sep 16, 2016||$0.028||Sep 30, 2016|
Many would like to follow Ark Investment Management founder Cathie Wood's vision due to her success. She says that digital wallets and genomics will be the next two biggest disruptive trends after Tesla...
The coronavirus pandemic could be a long-term positive for biopharma companies and the Invesco Dynamic Biotechnology & Genome ETF (PBE). PBE tracks the Dynamic Biotech & Genome Intellidex Index, which “...
Sector ETF report for PBE
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion ...
With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.
After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.
Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.
The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.
As the coronavirus continues to spread, the latest positive data on remdesivir is some relief in such challenging times.
The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.
Many biotech ETFs and other funds have fallen sharply off their highs in recent months.
Most of the financial markets have trended lower in recent weeks, but biotech seems to have countered the trend.
Sector ETF report for PBE